Recursion Pharmaceuticals Faces High Investment Risks Amid AI Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 11 2026
0mins
Should l Buy RXRX?
Source: NASDAQ.COM
Recursion Pharmaceuticals Inc. saw its stock rise by 5.00% as it crossed above the 5-day SMA, reflecting a positive trading session.
Despite this price increase, Recursion faces significant challenges in drug development, as highlighted in recent news. The company aims to transform drug development through its AI operating system, which could lower R&D costs and timelines. However, the lack of market-ready products and intense competition from larger pharmaceutical firms contribute to a high-risk investment profile, making it less appealing to conservative investors.
The implications of these challenges suggest that while the stock may experience short-term gains, the long-term outlook remains uncertain due to the competitive landscape and the need for successful product launches.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 7.75 USD with a low forecast of 5.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.560
Low
5.00
Averages
7.75
High
11.00
Current: 3.560
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Recursion Pharmaceuticals Leverages AI for Accelerated Drug Development
- AI Drug Development Platform: Recursion Pharmaceuticals' Recursion OS platform utilizes 65 petabytes of chemical and biological data to conduct virtual drug testing, significantly reducing clinical trial time and costs, allowing pharmaceutical companies to focus resources on their most promising drugs.
- Clinical Trial Progress: Currently, Recursion's drug development pipeline includes eight drugs, half of which are in actual clinical trials, indicating the effectiveness of its technology and market potential.
- Revenue Growth Expectations: Analysts anticipate Recursion's revenue will increase from last year's $62 million to $83 million this year, with projections reaching $163 million by 2028, primarily driven by R&D milestone payments from pharmaceutical partners.
- Industry Outlook and Risks: While the AI drug development sector is expected to grow at an average annual rate of 30% through 2034, Recursion faces risks related to profitability and competition, particularly from larger tech companies potentially entering the field.
See More
OpenAI Considers Investment in Biotech Sector
- Biotech Investment: OpenAI CEO Sam Altman stated that the company is considering investing in biotech firms that utilize AI for drug discovery, potentially earning royalties from the revenue generated, which could create a new revenue stream for OpenAI.
- No Current Partnerships: Currently, OpenAI has no partnerships with any biotech companies, but Altman emphasized that the frontier of scientific discovery will require significant capital, suggesting that OpenAI may act as an investor in certain cases.
- AI in Drug Development: Numerous pharmaceutical companies, including Recursion and Pfizer, are already leveraging AI in drug development, highlighting the immense potential and market demand in this sector, and OpenAI's investment could further accelerate this trend.
- Industry Insights: Altman's comments align with those made by OpenAI CFO Sarah Friar at the World Economic Forum, indicating that OpenAI may seek revenue shares from the applications of its AI tools, reflecting the company's focus on the future biotech market.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.
See More
High-Growth Stocks Underperform in 2025, Recovery Expected in 2026
- DraftKings Market Challenges: DraftKings shares fell 8% in 2025, closing 35% below their peak, primarily due to slowing industry growth and emerging competitors, yet brand strength and partnerships with NBCUniversal and ESPN will support future growth.
- Diversified Revenue Sources: Nearly half of DraftKings' revenue comes from casino-style gaming, and investors should focus on its broad revenue mix, which is expected to drive recovery in 2026.
- Recursion Drug Development Platform: Recursion Pharmaceuticals' stock dropped 44% in 2025, but its AI-powered drug discovery platform, Recursion OS, is poised to provide stronger technological proof in 2026, driving revenue growth.
- Future Revenue Expectations: Analysts forecast Recursion's revenue to reach $83 million in 2026, significantly up from $63 million in 2025, which will help reduce the company's losses and enhance its business viability.
See More
Recursion Pharmaceuticals Faces Challenges and Opportunities
- Expected Clinical Progress: Recursion Pharmaceuticals anticipates data readouts for its potential cancer drug REC-1245 in the first half of the year, although these phase 1 results will primarily focus on safety rather than efficacy, likely limiting stock impact.
- Intensifying Competition: With Eli Lilly developing the industry's most powerful supercomputer, Recursion faces fierce competition from larger pharmaceutical companies, which may hinder its long-term goal of licensing AI models.
- Poor Market Performance: Recursion's stock has significantly declined over the past year, with a current market cap of $2.4 billion and no approved products, indicating a high-risk business model.
- Investment Risk Warning: While Recursion claims its AI technology can enhance drug development efficiency, it has yet to prove its effectiveness, prompting investors to carefully consider the high volatility and risks involved.
See More
Recursion Pharmaceuticals Leverages AI for Accelerated Drug Development
- AI Drug Development Platform: Recursion Pharmaceuticals' Recursion OS platform utilizes 65 petabytes of chemical and biological data to conduct virtual drug testing, significantly reducing clinical trial time and costs, allowing pharmaceutical companies to focus resources on their most promising drugs.
- Clinical Trial Progress: Currently, Recursion's drug development pipeline includes eight drugs, half of which are in actual clinical trials, indicating the effectiveness of its technology and market potential.
- Revenue Growth Expectations: Analysts anticipate Recursion's revenue will increase from last year's $62 million to $83 million this year, with projections reaching $163 million by 2028, primarily driven by R&D milestone payments from pharmaceutical partners.
- Industry Outlook and Risks: While the AI drug development sector is expected to grow at an average annual rate of 30% through 2034, Recursion faces risks related to profitability and competition, particularly from larger tech companies potentially entering the field.
See More
OpenAI Considers Investment in Biotech Sector
- Biotech Investment: OpenAI CEO Sam Altman stated that the company is considering investing in biotech firms that utilize AI for drug discovery, potentially earning royalties from the revenue generated, which could create a new revenue stream for OpenAI.
- No Current Partnerships: Currently, OpenAI has no partnerships with any biotech companies, but Altman emphasized that the frontier of scientific discovery will require significant capital, suggesting that OpenAI may act as an investor in certain cases.
- AI in Drug Development: Numerous pharmaceutical companies, including Recursion and Pfizer, are already leveraging AI in drug development, highlighting the immense potential and market demand in this sector, and OpenAI's investment could further accelerate this trend.
- Industry Insights: Altman's comments align with those made by OpenAI CFO Sarah Friar at the World Economic Forum, indicating that OpenAI may seek revenue shares from the applications of its AI tools, reflecting the company's focus on the future biotech market.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.
See More
High-Growth Stocks Underperform in 2025, Recovery Expected in 2026
- DraftKings Market Challenges: DraftKings shares fell 8% in 2025, closing 35% below their peak, primarily due to slowing industry growth and emerging competitors, yet brand strength and partnerships with NBCUniversal and ESPN will support future growth.
- Diversified Revenue Sources: Nearly half of DraftKings' revenue comes from casino-style gaming, and investors should focus on its broad revenue mix, which is expected to drive recovery in 2026.
- Recursion Drug Development Platform: Recursion Pharmaceuticals' stock dropped 44% in 2025, but its AI-powered drug discovery platform, Recursion OS, is poised to provide stronger technological proof in 2026, driving revenue growth.
- Future Revenue Expectations: Analysts forecast Recursion's revenue to reach $83 million in 2026, significantly up from $63 million in 2025, which will help reduce the company's losses and enhance its business viability.
See More
Recursion Pharmaceuticals Faces Challenges and Opportunities
- Expected Clinical Progress: Recursion Pharmaceuticals anticipates data readouts for its potential cancer drug REC-1245 in the first half of the year, although these phase 1 results will primarily focus on safety rather than efficacy, likely limiting stock impact.
- Intensifying Competition: With Eli Lilly developing the industry's most powerful supercomputer, Recursion faces fierce competition from larger pharmaceutical companies, which may hinder its long-term goal of licensing AI models.
- Poor Market Performance: Recursion's stock has significantly declined over the past year, with a current market cap of $2.4 billion and no approved products, indicating a high-risk business model.
- Investment Risk Warning: While Recursion claims its AI technology can enhance drug development efficiency, it has yet to prove its effectiveness, prompting investors to carefully consider the high volatility and risks involved.
See More
